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1.  EXECUTIVE SUMMARY
1.1. INTRODUCTION
The World Health Organization estimates that 3.3 billion 
persons were at risk of acquiring malaria in 2006, with 247 
million of these developing clinical malaria (86% in Africa), 
and nearly 1 million (mostly African children) dying from 
the disease. Malaria remains endemic in 109 countries, and 
while parasite-based diagnosis is increasing, most suspected 
cases of malaria are still not properly identified, with 
accurate diagnosis and disease monitoring consequently 
remaining elusive (1).
WHO recommends that malaria case management be 
based on parasite-based diagnosis in all cases, with the 
exception of young children in areas of high transmission 
and where lack of resources or need for urgent response 
temporarily limits its application. The use of antigen-
detecting rapid diagnostic tests (RDTs) forms a vital part 
of this strategy, providing the possibility of parasite-based 
diagnosis in areas where good quality microscopy can not 
be maintained. The number of RDTs available, and the scale 
of their use, has rapidly increased over the past few years. 
However, limitations of comparative field trials and the 
heterogeneous nature of malaria transmission has limited 
the availability of good quality performance data that 
national malaria programmes require to make informed 
decisions on procurement and implementation. To this end 
in 2006, WHO and FIND (Foundation for Innovative New 
Diagnostics) launched an evaluation program to assess the 
performance of commercially available malaria RDTs and 
allow direct product comparisons that would assist WHO, 
other UN agencies and national governments in making 
procurement decisions and would ultimately encourage 
improvement in the quality of manufacturing.
1.2.  THE WHO PRODUCT TESTING  
PROGRAMME
This report, which presents the results of the first round of 
WHO product testing of malaria antigen-detecting RDTs, was 
completed in November 2008 in collaboration with FIND, the 
US Centers for Disease Control and Prevention (CDC) and 
other partners (Fig.2). All companies manufacturing under 
ISO-13485 Quality System Standard were invited to submit 
up to 3 tests for evaluation under the programme. In this 
first round of testing, 41 products from 21 manufacturers 
were evaluated against prepared blood panels of cultured 
Plasmodium falciparum parasites and patient-derived P. 
falciparum and P. vivax parasites, and a parasite-negative 
panel. Thermal stability was assessed after 2 months 
of storage at elevated temperature and humidity, and a 
descriptive ease of use assessment was recorded. Of the 
41 products, 16 detect P. falciparum alone, 22 detect and 
1 One is P. vivax specific
differentiate P. falciparum from non-P. falciparum malaria1, 
and 3 detect P. falciparum and non-P. falciparum malaria 
without distinguishing between them. Manufacturers 
submitted 2 lots of each product for evaluation. 
The evaluation is designed to provide comparative data 
on the performance of the submitted production lots of 
each product. Such data will be used to guide procurement 
decisions of WHO and other UN agencies and national 
governments. Product testing is part of a continuing 
programme of work to improve the quality of RDTs that 
are used, and to support broad implementation of reliable 
malaria diagnosis in areas where malaria is prevalent. A 
second round of product testing began in April 2009. It is 
anticipated that a further round will be undertaken in 2010, 
with a call for expressions of interest later in 2009.
1.3. RESULTS OF THE EVALUATION
The results (summarized in Tables 3, 3a, 4, 4a and Figure E1) 
provide comparative data on 2 lots of products against a 
panel of parasite samples diluted to a low parasite density 
(200 parasites/μL) and a higher parasite density (2000 or 
5000 parasites/μL). The former is below the mean parasite 
density found in many populations with endemic malaria. 
For the purposes of this report, 'detection rate' of a product 
is the percentage of malaria samples in the panel giving 
a positive result by two RDTs per lot at the lower parasite 
density, and a single RDT per lot at the higher parasite 
density. Thus, it is not a measure of RDT clinical sensitivity, 
or positivity rate against the panel but rather a combined 
measure of positivity rate, along with inter-test and inter-
lot consistency. 
The clinical sensitivity of an RDT to detect malaria is highly 
dependent on the local conditions, including parasite 
density, in the target population, and so will vary highly 
between malaria-endemic populations. The results in this 
report show comparative performance between RDTs, and 
give an idea of which products are likely to provide higher 
sensitivity in the field, particularly in populations with low-
density infections. As the detection rate at 2000 parasites/
μL indicates, the sensitivity of many of these products will 
be similar in populations with higher parasite densities, 
although a subset of any population will include vulnerable 
individuals who may develop illness at low parasite densities 
(e.g. young children, pregnant women, those well protected 
by bed nets) and must always be taken into account when 
interpreting RDT results. 
Heat stability (summarized in Table 5) is vital to maintaining 
sensitivity of the test in the field. As a result, for 
procurement, it is essential that careful consideration be 
given to stability results to ensure that products to be used 
in areas with high temperatures of transport and storage 
have demonstrated great stability in the product testing 
programme. Requirements will vary between countries: 
for example, if tests are to be deployed in areas where 
temperatures rarely rise above 30°C, less emphasis needs to 
be placed on stability at high temperatures. 
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Figure E1: Summary performance of malaria RDTs against blood samples containing wild type P. falciparum 
at low (200) and high (2000 or 5000) parasite densities (parasites/μl) and malaria-negative samples.

















































































































































































































































































































































































































































































































































































































































































200 parasites/µl (non HRP2)
2000 or 5000 parasites/µl (HRP2)












Pf - Plasmodium falciparum 
Pv - Plasmodium vivax
pan - Plasmodium species 
‡ - A sample is considered detected only if all RDTs from both lots read by the first technician, at minimum specified reading time, are positive. Phase 
2 Evaluation Panel: 79 P. falciparum wild type samples; 20 P. vivax wild type samples and 90 Plasmodium spp. negative samples. Rapid diagnostic 
tests (RDTs) - 2 tests x 2 lots at 200 parasites/µl and 1 test x 2 lots at 2000 parasites/µl
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Ease of use  requirements will also vary, depending on 
the extent of training and the work environment of the 
end-users. Particularly in primary health care settings, the 
simpler the tests, the easier it will be to avoid errors in 
preparation and interpretation.
1.4. SUMMARY OF OUTCOMES
 There is now a mechanism in place that allows •	
laboratory-based evaluation of RDT performance in 
a standardized way to distinguish between well and 
poorly performing tests to inform procurement and 
prioritization for entry into WHO prequalification and 
procurement schemes.
 Several RDTs are available that demonstrated consistent •	
detection of malaria at low parasite densities (200 
parasites/μl), have low false positive rates, are stable 
at tropical temperatures, are relatively easy to use, and 
can detect P. falciparum, P. vivax infections, or both. 
 Performance between products varied widely at low •	
parasite density (200 parasites/μl); however, most 
products showed a high level of detection at 2000 or 
5000 parasites/μl. 
 •	 P. falciparum tests targeting HRP2 antigen demonstrated 
the highest detection rates, but some tests targeting 
pLDH also exhibited high detection rates. 
 Test performance varied between lots, and widely •	
between similar products, confirming the advisability of 
lot-testing post purchase and prior to use in the field.
 The results underscore the need for manufacturers •	
to have adequate reference materials for product 
development and lot-release. The WHO-FIND malaria 
RDT evaluation programme, in collaboration with 
the CDC, will soon offer quality standard panels to 
manufacturers to assist in this process. 
1.5. USE OF THESE RESULTS
Ultimately, it is imperative that procurement decisions 
based on these results take into consideration local 
conditions of malaria transmission and illness where the 
tests will be used (e.g. Plasmodium species, target antigen 
variation, parasite densities, climate). Procurement of RDTs 
must not occur without programmatic and infrastructure 
preparation for proper use, including supply chain 
management, training on test usage and disposal, and 
training on patient management in response to results. 
This report provides an algorithm to assist in this decision-
making process (Annex 5). 
2. BACKGROUND
In 2006, WHO estimated that 3.3 billion persons were 
at risk of acquiring malaria. Of these, 247 million were 
infected (86% in Africa) and nearly 1 million (mostly 
African children) died of the infection. In 2008, malaria 
was still endemic in 109 countries worldwide, 45 of them 
in Africa. WHO estimates that approximately 1.1 million 
persons were still dying of malaria that year (1).
In the past decade, major new opportunities for the control 
of malaria have emerged, including implementation of 
long-lasting insecticidal nets, indoor residual spraying of 
insecticides and artemisinin-based combination therapy 
(ACT). These tools, in combination with increased coverage 
of malaria control programs, are likely to reduce the burden 
of malaria infection in countries where they are adequately 
implemented. In turn, the proportion of febrile episodes 
attributable to malaria is likely to decrease substantially. 
Despite WHO recommendations for laboratory-confirmed 
diagnosis of malaria infections2, diagnosis is often made 
2 With the exception of children under 5 years of age in areas of high 
transmission in whom treatment may be provided on the basis of a 
clinical diagnosis
on clinical grounds (2). However, in most endemic areas 
malaria makes up a minority of 'malaria-like' febrile illness. 
Microscopy has been the cornerstone of diagnosis and 
remains the recommended method of malaria diagnosis 
at a central level, but the need for trained personnel, 
adequate reagents and equipment limit its availability and 
accessibility. Rapid, accurate and accessible diagnostic 
tools are becoming increasingly important, as programmes 
expand parasite-based diagnosis and the prevalence 
of malaria decreases. In recent years, rapid diagnostic 
tests (RDTs), which detect Plasmodium-specific antigens 
(proteins) in whole blood of infected people, have emerged 
as an attractive alternative to microscopy. Currently 
available RDTs come in various formats (dipstick, cassette 
or card) and contain bound antibodies to specific antigens 
such as histidine-rich protein-2 (HRP2) (specific to P. 
falciparum), pan-specific or species-specific plasmodium 
lactate dehydrogenase (pLDH) or aldolase (specific to all 
the major Plasmodium species: P. falciparum, P. vivax, P. 
malariae, P. ovale (Figure 1). 
To be widely useful, a RDT must have high sensitivity to ensure 
all clinically-significant malaria infections are detected; 
high specificity to enable monitoring of low malaria 
prevalence and appropriate management of non-malarial 
fever; and high stability to allow transport and storage in 
ambient conditions in malaria-endemic areas. Published 
field trials of RDTs show high variability in performance, 
likely due to inadequate quality of manufacture, incorrect 
storage and handling, poor preparation and interpretation, 





































Figure 1: Mode of action of antigen-detecting malaria RDTs
Mode of action of common malaria RDT 
format: (a) Dye-labeled antibody (Ab), specific 
for target antigen, is present on the lower end 
of the nitrocellulose strip or in a well provided 
with the strip. Antibody, also specific for the 
target antigen, is bound to the strip in a thin 
(test) line, and either antibody specific for the 
labeled antibody, or antigen, is bound at the 
control line. (b) Blood and buffer, which have 
been placed on the strip or in the well, are 
mixed with the labeled antibody and are drawn 
up the strip across the lines of bound antibody. 
(c) If antigen is present, some labeled antibody 
will be trapped on the test line. Other labeled 
antibody is trapped on the control line.
and sometimes poor study methods, analysis and reporting 
( 3-11).
The number of RDTs available on the market has grown 
rapidly since their introduction in the late 1990s. It is 
estimated that there are 60 brands and over 200 tests 
commercially available today, with an estimated 50-70 
million tests used in 20083. However, regulatory oversight 
of diagnostics is often weak, and procurement agencies 
have faced considerable problems in selecting appropriate 
RDTs and ensuring quality. In view of the inconsistency 
in field study results and the inherent difficulties in 
3 WHO. Unpublished data 
assessing large numbers of products in a standardized way 
through field trials, WHO and various partners embarked 
on a Malaria Rapid Diagnostic Test Product Evaluation 
Programme in 2002 to develop and employ standardized 
assessment of malaria RDT performance, and to guide 
procurement decisions and regulatory mechanisms. The 
Programme has been overseen by WPRO and TDR in 
partnership with FIND, and has been guided by a Steering 
Committee4 and several consultations from 2003 to 2008. 
A network of specimen collection sites was established to 
contribute specimens to a global bank at the US CDC and 
to facilitate local quality control activities (Figure 2).
4 WHO/FIND/CDC, Methods manual for product testing of malaria rapid 
diagnostic tests (version 1). 2008
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3. OBJECTIVES
 Evaluate malaria RDTs to produce performance data •	
that can guide procurement of RDTs for use in the field. 
Areas where malaria transmission occurs
Areas with limited risk of malaria transmission
No malaria
This map is intended as a visual aid only and not as a definitive source of information about malaria endemicity. Source: © WHO, 2009. All rights reserved.














Figure 2: Network of specimen collection, characterization and testing sites
Abbreviations: AMI Army Malaria Institute (Queensland, Australia); CDC Centers for Disease Control and Prevention (Atlanta, United 
States of America); CIDEIM Centro Internacional de Entrenamiento y Investigaciones Médicas (Cali, Colombia); DMR Experimental 
Medicine Research Division (Department of Medical Research, Yangon, Myanmar); HTD Hospital for Tropical Diseases (London, United 
Kingdom of Great Britain and Ireland); IHRDC Ifakara Health Research and Development Center (Bagamoyo, The United Republic of 
Tanzania); IMT Instituto de Medicina Tropical (Universidad Peruana Cayetano Heredia, Lima, Peru); IPB Institut Pasteur de Bangui 
(Bangui, Central African Republic); IPC Institut Pasteur du Cambodge (Phnom Penh, Cambodia); IPM Institut Pasteur de Madagascar 
(Antananarivo, Madagascar); RITM Research Institute of Tropical Medicine (Manila, Philippines); UL University of Lagos (Lagos, 
Nigeria).
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4.  MATERIALS AND 
METHODS
4.1. TEST SELECTION 
In August 2007, the WHO-FIND Malaria RDT Evaluation 
Programme issued a call for expression of interest to 
manufacturers of malaria RDTs along with information 
regarding the requirements for submission of a product 
and the conditions for participation in the Evaluation 
Programme5. Requirements included: ISO 13485:2003 
5 http://www.wpro.who.int/sites/rdt/who_rdt_evaluation/ 
 (accessed 08 April 2009)
certification, supply of sufficient quantities of products 
(1100 tests from each of 2 lots), and compliance with in-
house real time stability testing protocol6.
After an initial call for expressions of interest, 21 
manufacturers submitted a total of 41 products to be 
included in Round 1 (including 2 co-listed (identical) 
products). 
In summary, of the 41 products: 16 detect P. falciparum 
alone, 22 detect and differentiate P. falciparum from 
non-P. falciparum malaria7, and 3 detect P. falciparum and 
non-P. falciparum malaria without distinguishing between 
them. Annexes 1 and 2 provide a comprehensive overview 
of product characteristics. 
6 Methods Manual for Product Testing of Malaria RDT Version One 2008. 
SOP 2.2d; available at www.wpro.who.int/sites/rdt/documents.htm 
(accessed 08 April 2009)
7 One is P. vivax specific
Table 1:  Manufacturers and products accepted into Round 1 of WHO-FIND Malaria RDT Evaluation 
Programme
Manufacturer Product name Catalogue No.* Target Antigen
Access Bio, Inc.
CareStart Malaria HRP2 (Pf)
CareStart Malaria HRP2/pLDH (Pf/PAN) COMBO







ACON Laboratories, Inc. Malaria Plasmodium falciparum Rapid test Device (Whole blood) IMA-402 HRP2
Amgenix International, Inc. OnSight – ParaQuick (Pan, Pf) Test 536-25DB HRP2/pLDH








Diagnostics Automation/  
Cortez Diagnostics, Inc.
Malaria P.F/Vivax 17211OP-25 HRP2/aldolase








IND Diagnostic Inc. One Step Malaria Antigen Strip 820-1 pLDH
Innovatek Medical Inc.
Quickstick Malaria Antigen Test 
(Co- listing with IND Diagnostics Inc. One Step Malaria Antigen Strip)**
-- pLDH
InTec Products, Inc.
ADVANCED QUALITYTM One Step Malaria (p.f.) Test (whole blood)





Inverness Medical Innovations, Inc. Binax Now Malaria IN660050 HRP2/aldolase
J. Mitra & Co. Pvt. Ltd.
Advantage Pan Malaria Card
Advantage P.f. Malaria Card    








Paracheck Pf Rapid test for P. falciparum Malaria (Device) 





Premier Medical Corporation Ltd.
First Response Malaria Ag HRP2






ICT Malaria Pf Cassette Test (ML01)






Parahit-f DIPSTICK FOR FALCIPARUM MALARIA
Parahit-f TEST DEVICE FOR FALCIPARUM MALARIA









SD BIOLINE Malaria Ag
SD BIOLINE Malaria Ag Pf 








FirstSign – Malaria Pf Card Test





Vision Biotech (Pty) Ltd.
Malaria Rapid Pf
Malaria Rapid Combo







Guangzhou Wondfo Biotech Co., Ltd Wondfo One Step Malaria Pf/Pan Whole Blood Test W56-C (4.0 mm) HRP2/pLDH
Zephyr Biomedicals
Parascreen Rapid Test for Malaria Pan/Pf (Device)
Malascan Rapid Test for Malaria Pf/Pan (Device)







*  Some products may include different catalogue numbers for different box sizes, contact manufacturers for details.
** Co-listing: One product is submitted for assessment. Manufacturers confirm that second product is identical with different label.
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Participating manufacturers received results of test 
performance and reproducibility prior to publication.
4.2.  OUTLINE OF THE PRODUCT TESTING 
PROTOCOL 
The testing process is outlined in Figure 3 and in the 
Methods Manual for Product Testing of Malaria Rapid 
Diagnostic Tests - Version One8. In brief, RDTs from each 
of two lots of each product were evaluated against a panel 
of parasite-positive and parasite-negative cryo-preserved 
blood samples, and a panel of parasite-negative samples. 
Both lots were also tested for heat (thermal) stability, 
evaluated before and after 2 months’ storage at 4°C, 
35°C and 45°C. Finally, an ease-of-use description was 
developed using a standard assessment format (Figure 3). 
The testing process and all results were overseen by the 
specimen bank steering committee, and manufacturers 
were given an opportunity to comment on individual 
product results prior to publication.
8 Available at www.wpro.who.int/sites/rdt/documents.htm
4.3. EVALUATION PANELS
RDTs were evaluated against three panels, specifically: 
i) P. falciparum culture lines (includes a subset, 
'manufacturer's panel') at low (200 parasites/μl) and 
high parasite densities (2000 or 5000 parasites/μl).
ii) Wild-type Plasmodium species (P. falciparum, P. vivax) 
from naturally infected humans and parasite-negative 
samples at low (200 parasites/μl) and high parasite 
densities (2000 or 5000 parasites/μl).
iii) Parasite-negative panel ('clean' samples and disease-
specific or blood factor-specific samples).
An overview of the sample collection and 
characterization process can be found in the "Outline 
of Product Testing and Associated Protocols"9 and 
detailed methods manuals prepared for laboratory 
quality control10 and product testing of malaria 
RDTs9-15. Characterization results can be found at 
www.wpro.who.int/sites/rdt .
9 Initiative for Quality Assurance of Malaria Rapid Diagnostic Tests: Outline 
of product testing and associated protocols; available at www.wpro.who.
int/sites/rdt/documents.htm (accessed 08 April 2009)
10 Methods Manual for Laboratory Quality Control Testing of Malaria Rapid 
Diagnostic Test Version 5a available at 
 www.wpro.who.int/sites/rdt/documents.htm (accessed 08 April 2009)
TEST RDTS AGAINST HIGH 
AND LOW DENSITY OF PHASE 1 
PANEL
RECORD RESULTS RECORD RESULTS 
DETECTION RATE AND 
FALSE POSITIVE RATE
 
EASE OF USE DESCRIPTION





PROCEED TO TEST RDTS 
AGAINST PHASE 2 PANEL, IF 
PASS PHASE 1
IN EACH CASE, READ EACH 
RESULT WITH:
TECH 1 TECH 2
BLOOD SAFETY
NUMBER OF TIMED STEPS 
TOTAL TIME TO 
OBTAIN RESULT







• BLOOD TRANSFER METHOD
• ITEMS INCLUDED 
 IN PACKAGE
• LANGUAGE 
SELECT RDTS FROM 2 DIFFERENT LOTS
STORE FOR 2 MONTHS AT 75% HUMIDITY








 2000 p/µl 
SAMPLE
PLACE IN A 
35°C 
INCUBATOR





INITIAL TEST VS. 
200, 2000 p/µl 
Figure 3: Malaria RDT Product Testing Overview 
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Figure 4b: Origin of P. vivax wild type samples 
In summary, each panel specimen was characterized for: 
i) Geographical origin
ii) Species by duplicate microscopy11 (two microscopists) 
and confirmation by nested PCR of mono-species 
infection12
iii) HRP2 sequence by PCR amplification13
iv) Antigen concentration, determined by quantitative 
ELISA for HRP2, pLDH, aldolase14
v) PCR for malaria and confirmatory testing for other 
pathology in the case of parasite-negative samples
Panel composition
P. falciparum-cultured parasites panel 
Twenty culture-adapted strains of P. falciparum of varied 
geographical origin were selected, including 13 strains with 
type B HRP2 sequence, 5 with Type A, and 3 with Type C 
HRP2 sequence. All specimens were derived from the culture 
bank of US CDC, and diluted in O+ US donor blood15. 
Wild type parasite panel 
The parasite-positive wild type panel consisted of samples 
from 79 cases of P. falciparum and 20 cases of P. vivax, 
derived from 9 collection sites in Asia, Africa and South 
America (Figs 2, 4a and 4b).
11 Methods Manual for Product Testing of Malaria RDTs Version One 2008. 
Chapter 4 SOP 4.5, 4.6
12 Methods Manual for Product Testing of Malaria RDTs Version One 2008 
Chapter 5 SOP 5.7, 5.8
13 Methods Manual for Product Testing of Malaria RDTs Version One 2008 
Chapter 5 SOP 5.9
14  Methods Manual for Product Testing of Malaria RDTs Version One 2008 
Chapter 5 SOP 5.1-5.6
15  Methods Manual for Product Testing of Malaria RDTs Version One 2008. 
Chapter 3 SOP 3.9
Samples were collected from febrile patients and processed 
according to standardized methods designed to preserve 
target antigen concentration16. After dilutions and cryo-
preservation, samples were transferred to the global bank 
at US CDC for further characterization. The distribution of 
concentration of HRP2, aldolase and pLDH were determined 
on a larger sample, and a test panel developed that 
excluded samples with extremes of high or low antigen 
concentration. 
Negative blood samples
The negative panel consisted of 'clean' parasite-negative 
samples from donor-derived blood banks in non-endemic 
areas of the Philippines, Madagascar, USA, and Nigeria, 
and parasite-negative samples from donors with diseases 
that may potentially be differential diagnoses of malaria, 
or with specific blood factors known to be common in 
the community or known to have the potential to cause 
false positive reactions on immunochromatographic tests 
(Table 2). Further details of the parasite-negative panel are 
found at http://www.wpro.who.int/sites/rdt. 
16 Methods Manual for Laboratory Quality Control Testing of Malaria Rapid 
Diagnostic Tests Version 5a Chapter 3; available at www.wpro.who.int/
sites/rdt/documents.htm
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4.4. RDT REGISTRATION
The receipt of each shipment of RDTs at the evaluation centre 
was recorded in a dedicated RDT register. Temperature 
monitoring devices were offered to manufacturers free 
of charge, to accompany RDTs shipments to CDC. All 
RDTs were stored at ≤ 25°C immediately and temperature 
monitors were labeled with receipt date and forwarded for 
downloading, when applicable.
4.5. SPECIMEN PANEL REGISTRATION
All panel specimens were assigned unique identification 
numbers at the collection sites and stored in aliquots of 
50μl at -70°C until the time of testing. All data pertaining 
to specimen ID, storage location and characteristics was 
stored in a dedicated database.
4.6. TEST PHASES
The evaluation was divided into two testing phases: 
Phase 1 - A first screening step to allow the selection of RDTs 
meeting minimal quality requirements. Products from two 
lots were evaluated against a panel of 20 culture-derived P. 
falciparum samples at high (2000 or 5000 parasites/μl) and 
low (200 parasites/μl) parasite densities.
Phase 2 - Products from two lots were evaluated against 
a panel of blood samples containing wild type parasites 
and a parasite-negative panel, evaluated for heat (thermal) 
stability, and assessed for ease of use:
a.  The parasite-positive and parasite-negative panel was 
comprised of 79 P. falciparum, 20 P. vivax at two parasite 
densities (200 parasites/μl and 2000 or 5000 parasites/
μl), and 90 parasite-negative controls. 
b.  Heat stability evaluation: Baseline testing of 10 RDTs 
from each of two lots against a single culture-derived 
isolate (Nigeria XII strain, Pf HRP2 sequence type B with 
a typical antigen concentration) at 200 parasites/μl and 
2000 parasites/μl and 4 RDTs from each lot against a 
negative sample. This procedure was repeated after RDTs 
were maintained for 60 days at 4°C, 35°C and 45°C at 
75% humidity. 
Figure 5: Testing procedure for Product A against a sample density of 2000 or 5000 parasites/μl
The first reading was at the minimum time specified by the manufacturer; the second reading was up to one hour 
later and contributed to the determination of the final result only if the manufacturer specified that reading should 
be repeated if the initial reading was negative for malaria.
Based on positive results of the first test reading in each lot, the mean band intensity score =a+b/2 
Total number  
of tests =2
Total number  
of tests x readings =4
product a
a b
Reading 1 Reading 2
Lot 1
Test 1
Reading 3 Reading 4
Lot 2
Test 2
Table 2:  Characteristics of Plasmodium spp. 
negative specimens
Nature of negative sample1 No
‘Clean’ negative2 42
Anti-nuclear antibody positive (sera) 13
Anti-mouse antibody positive (plasma) 1
Rheumatoid factor positive (whole blood and sera) 4
Rapid plasma reagin positive (sera) 9
Chagas’ disease antibody positive (plasma) 2
Dengue antibody positive (whole blood and sera) 4
Leishmaniasis antibody positive (sera) 5
Schistosomiasis antibody positive (whole blood and sera) 10
1  Whole blood unless indicated. Sera and plasma samples were reconstituted 
packed cells
2  Healthy volunteers with no known current illness or blood abnormality
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c.  Ease of use assessment: After becoming familiar with 
the test device, technicians jointly described the test 
for blood safety characteristics, quality of instructions, 
number of timed steps and total time to result, using a 
standard reference guide17.
d.  A stability assessment was also required to be conducted 
by manufacturers at the manufacturing site. Manufac-
turers were requested to assess real-time heat stability 
at three month intervals against high and low parasite 
densities supplied by WHO at the upper limit of their 
recommended storage temperature throughout shelf-
life and at the end of shelf-life. Results are submitted to 
WHO at regular intervals, for internal use, only.
4.7. PERFORMING RAPID TESTS
All RDTs were brought to room temperature prior to first 
use. Desiccant was inspected for colour changes and 
products were discarded if present. RDTs were labeled 
with patient ID, dilution, and the date when test was 
performed. Performance of rapid tests was in accordance 
with manufacturer’s instructions, with the exception that 
blood transfer was carried out by micro-pipette from the 
sample tube. The result was recorded by a technician at the 
17 Methods Manual for Product Testing of Malaria RDTs Version One 2008. 
Chapter 7, available at www.wpro.who.int/sites/rdt/documents.htm
minimum specified reading time and by a second technician 
within 1 hour. Technicians were rotated, and blinded to 
sample type and to each other's results during Phase 
II. Annexes 1 and 2 contain a descriptive and illustrated 
summary of the test characteristics, steps and guide to 
interpretation of results.
 
4.8. INTERPRETATION OF RESULTS
Results of control and test lines were recorded as negative 
or positive by each technician. Each test was read against 
a standard colour chart and the band intensity graded as 
0 (no band), 1, 2, 3 or 4. If the control line is recorded as 
absent by either technician, the test is recorded as invalid. 
Figures 5 and 6 illustrate the testing sequence at low and 
high parasite densities.
Figure 6: Testing procedure for Product A against a sample density of 200 parasites/μl 
The first reading was at the minimum time specified by the manufacturer; the second reading was up to one hour 
later and contributed to the determination of the final result only if the manufacturer specified that reading should 
be repeated if the initial reading was negative for malaria. 




Test 1 Test 2
Lot 1
Reading 1 Reading 2
Test 3 Test 4
Lot 2
Reading 3 Reading 4
Total number  
of tests =4
Total number  
of tests x readings =8
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 5. DATA MANAGEMENT 
The receipt of products was hand recorded in an RDT 
register at the CDC as per Standard Operating Procedures 
(SOPs). Data associated with specimen collection and 
characterization was recorded first on hard copy report 
forms as per the SOPs at the collection sites (Figure 2), HTD 
(ELISA reporting) and CDC (PCR) and then entered directly 
into formatted excel spreadsheets that were subsequently 
imported into a specially developed database. 
The results of the product panel testing and heat stability 
testing conducted at the CDC were recorded on report 
forms by each technician individually, as per the SOP. 
These results were transferred to a Master Results Sheet 
and subsequently registered in the database via one of two 
mechanisms: i) direct database entry or ii) into an excel 
spreadsheet formatted for subsequent importation into the 
database. 
In order to control for data entry errors, all data discrepancies 
between Reader 1 and Reader 2 were resolved through 
inspection of the original hard copy report forms. 
All source documents and electronic records of study data 
have been kept in secure areas until the conclusion of the 
evaluation, data analysis and report publication. 
Individual product testing reports and accompanying raw 
data were assembled for manufacturers’ review 60 days 
prior to release of the published report. 
6. QUALITY ASSURANCE 
Product testing followed SOPs developed through prior 
testing experience and based on recommendations of 
expert consultations6,8. A pilot phase using a limited 
number of tests and an abbreviated panel was conducted 
to refine these procedures. The quality of critical steps was 
controlled, as follows:
 Quality of the malaria RDTs and their use:•	
All RDTs were stored in a controlled environment at ≤ 25°C; 
the pouch was opened and desiccant checked immediately 
before use; manufacturer instructions were followed with 
the exception of use of the blood transfer device provided 
by the manufacturer (a micropipette was used to ensure 
correct blood volume).
A temperature-monitoring device was offered to be included 
with the RDTs for shipment to the testing site.
Quality and objectivity of the RDT reading results:•	
 Results were read in good lighting by trained technicians 
tested for visual acuity. Technicians were rotated. Readings 
of a second technician were reported for discrepant rates; 
it should be noted that these may have been affected by 
changes in presence or intensity of test lines with time.
 All wild parasite samples at low parasite density were first 
randomized with a similar number of negative control 
samples and re-labeled for blinded reading of the RDT 
results.
Quality of the specimen bank samples:•	
 SOPs were established for the preparation of all specimen 
bank samples8. Culture lines of parasites and wild-type 
samples were selected taking into account previous 
evidence and data from specifically conducted studies. All 
diluted parasite samples were stored and transported at 
-70°C, and were used only once within 8 hours of thawing. 
Quality of the product testing site: •	
 The Malaria Branch, Division of Parasitic Diseases at the 
Centers for Disease Control and Prevention (CDC, Atlanta, 
USA) is one of the major operating components of the 
Department of Health and Human Services (HHS) of the 
USA. The laboratory holds Clinical Laboratory Improvement 
Amendments (CLIA) accreditation and is monitored by 
internal Quality Management Systems (QMS) programmes.
MALARIA RAPID DIAGNOSTIC TEST PERFORMANCE – Results of WHO product testing of malaria RDTs: Round 1 (2008)
12
7.  ETHICAL 
CONSIDERATIONS
Each specimen collection site obtained approval from 
a WHO Research Ethics Review Committee and local 
institutional review board for specimen collection, transport 
and archiving of blood samples for the purpose of product 
testing, lot testing and quality assurance procedures.
8. DATA ANALYSIS 
8.1.  DEFINING SENSITIVITY AND SPECIFICITY/
DETECTION AND FALSE POSITIVE RATES
Malaria RDTs detect parasite-derived antigen. The 
relationship of the concentration of antigen available from 
the blood sample (after lysis of red cells and parasites) to 
the peripheral parasite density varies highly due to a series 
of host and parasite factors. The population frequency of 
specific factors that may result in false positive results 
may also vary. Therefore, field sensitivity and specificity 
of an RDT may change in different epidemiological 
situations. The evaluation reported here does not predict 
sensitivity or specificity in a given field situation. It reports 
comparative detection of target antigens and false positive 
rates of RDTs against a standardized panel, in a controlled, 
repeatable manner. As the panel is developed to be a close 
approximation of field samples, the comparative detection 
rates between products are expected to be reflected by 
similar comparative detection rates in the field. As the 
panel is designed to include a large number of samples 
close to the limits of detection of RDTs, the panel is likely 
to discriminate more clearly than a field trial. It follows that 
in some settings, such as where parasite density is very 
high, differences in detection rates between tests observed 
against the WHO evaluation panel may not be observed in 
patient populations. Furthermore, where parasite densities 
are very low, detection rates may be lower than those 
reported here.
Referring to Figure 6, to be classified as detecting a sample, 
a product must return 4 positive tests at the manufacturers’ 
recommended minimum reading time (2 from Lot 1, 2 from 
Lot 2 at initial reading time) when tested using a parasite 
density of 200 parasites/μl. When tested against 2000 or 
5000 parasites/μl (Figure 5) the product must return 2 
positive tests at the manufacturers’ recommended minimum 
reading time (1 from each lot). Thus, a “positive” result is a 
measure of consistency of result, as well as ability to detect 
antigen. 
The detection rate was defined as the percentage of P. 
falciparum wild type samples detected by the product. 
The non-P. falciparum detection rate is the percentage 
of Plasmodium positive/P. falciparum negative samples 
identified by the product.
8.2. FALSE POSITIVES
False positive results are analysed and reported as 
two separate groups; those that had incorrect species 
identification, and those that returned a positive result 
for samples containing no Plasmodium spp. parasites. 
Specifically, the false positive rate is the percentage of all 
tests that returned a positive test when it shouldn't have, 
based on reader 1 results.
8.2.1. Incorrect species identification
A test is considered as returning an incorrect species result 
if a positive P. falciparum test line appears with a sample 
containing non-P. falciparum parasites. P. vivax samples 
resulting in a visible line on a P. falciparum-specific test 
line are also considered to be false positives.
8.2.2.  False positives from Plasmodium-negative 
samples
Any test that produces a positive reading to samples with 
no Plasmodium parasites is considered a false-positive. 
In Phase 2, parasite-negative samples consist of clean 
negative samples and also samples containing other 
infectious agents (e.g. Dengue, Leishmania, Chagas) and 
immunological factors (rheumatoid factor, anti-nuclear 
antibodies, heterophile antibodies).
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 8.3. BAND INTENSITY
All positive tests results were recorded according to the 
band intensity against a standard reference chart, matched 
closely to line colour. Based on Reader 1 results, the 
distribution of band intensity results is presented as the 
mean band intensity of positive results. In addition, the 
intensity was expressed for each possible result (0, 1, 2, 3 
or 4)18 as the percentage recorded at that level.
8.4. LOT AGREEMENT 
Disagreement between test lots is calculated from the 
number of samples that returned a positive result on both 
RDTs tested in that lot against parasite-positive samples 
at 200 parasites/μl, and on the single RDT from each lot 
tested against samples at 2000 or 5000 parasites/μl. Thus, 
high inter-lot agreement indicates consistency in detecting 
malaria parasites.
18 A standard intensity comparison chart is used, allowing matching to the 
closest of 4 common colour variants of labelled antibodies used on RDTs, 
each at 4 levels of intensity.
8.5. READER VARIABILITY
Two readings of each test are conducted, although only the 
first is certain to comply with the manufacturer’s guidelines 
for reading test results. A second reading is performed within 
one hour. Detection rates for both readers are calculated to 
assess how sensitive the results are to the time of reading.
8.6. INVALID TESTS
The total number of tests that were deemed invalid during 
testing of both lots, using samples at 200 parasites/μl and 
2000 or 5000 parasites/μl.
8.7. HEAT (THERMAL) STABILITY 
The results of heat stability testing are reported as the 
number of positive tests (maximum 10) and mean band 
intensity (for positive tests only) per lot at baseline and 
after lots were stored at 4°C, 35°C and 45°C for 2 months 
against one P. falciparum parasite sample at 200 and 2000 
parasites/μl. 
9.  LABORATORY VERSUS 
FIELD-BASED MALARIA 
RDT EVALUATIONS
Despite the strengths of the product testing programme, 
the evaluation is not completely analogous to field testing 
of malaria RDTs. In order to compose a panel that could 
be reproducibly used to evaluate RDTs, blood samples were 
diluted, frozen and stored below −70°C. Blood that has 
undergone a freeze thaw process may not have exactly the 
same characteristics as fresh blood, but as red cell lysis 
occurs as a first step on RDTs, the effect of this is limited. 
A further variation from field equivalence is the use of a 
micro-pipette to supply blood to the RDT device rather than 
the blood transfer device provided by the manufacturer. 
This was necessary because blood is collected from a cryo-
tube rather than a finger-prick. This technique also ensured 
consistency of testing by reducing the likelihood of operator 
error.




In Round 1 of the WHO-FIND Malaria RDT Evaluation 
Programme, 41 products were evaluated against P. 
falciparum culture samples, blood samples collected from 
parasitaemic patients from three continents and a large 
panel of parasite negative samples. Heat stability was 
assessed at temperatures commonly encountered in malaria 
endemic countries. Twelve research institutes were engaged 
in either sample collection or sample characterization to 
establish the evaluation panels. Between May and November 
2008, in total, over 41 000 tests were performed at the US 
Centers for Disease Control and Prevention. 
The results of the evaluation reveal the following key 
outcomes: 
1.  Several RDTs are available that demonstrated consistent 
detection of malaria at low parasite densities (200 
parasites/μl), have low false-positive rates, are stable at 
tropical temperatures, are relatively easy to use, and can 
detect P. falciparum, P. vivax infections, or both. 
2.  Performance between products varied widely at low 
parasite density (200 parasites/μl); however, most 
products showed a high level of detection at 2000 to 
5000 parasites/μl. 
3.  P. falciparum tests targeting HRP2 antigen demonstrated 
the highest detection rates, but some tests targeting 
pLDH also exhibited high detection rates. 
4.  Test performance varied between lots, and widely 
between similar products. 
Tables 3 and 4 summarize the performance of 41 malaria RDTs 
against P. falciparum cultured parasites (Table 3) and blood 
containing wild type P. falciparum and P. vivax parasites 
and Plasmodium spp. negative samples (Table 4). Tables 
3a and 4a present summary results for 7 products based 
on a delayed reading when specified in the manufacturers' 
instructions. Detailed information pertaining to all product 
testing results is included in Annex 3 (Phase 1) and Annex 
4 (Phase 2). A graphical representation of this data follows 
below. 
In summary tables, data is colour coded according to 
arbitrary categories, to ease the interpretation of results, 
and these do not imply limits of acceptable or unacceptable 
performance. 
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2 0
10.2.  PHASE 1 - P. FALCIPARUM CULTURE 
PANEL
 The majority (73%) of tests consistently detected ≥ 95% of 
P. falciparum cultured parasites at high parasite densities; 
however, detection rate was highly variable at low parasite 
densities (0-100%). At low parasite densities, the top ten 
products all targeted HRP2 (Figure 7). 
Table 3a illustrates detection rates at low and high 
parasite densities based on a delayed second reading if it 
was specifically indicated in the package insert following 
initial negative results at the specified reading time. For 















































































































































































































































































































































































































































































































































































































































































































































































Figure 7: Phase 1 P. falciparum detection rate of malaria RDTs at low (200) and high (2000 or 5000) 
parasite densities (parasites/μl) according to target antigen type (HRP2 or pLDH)† 
† - Phase 1 Evaluation Panel : 20 P. falciparum culture samples. RDTs - 2 tests x 2 lots at 200 parasites/μl ; 1 test x 2 lots at 2000 parasites/μl. 
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 10.3.  PHASE 2 - WILD TYPE P. FALCIPARUM 
AND P. VIVAX AND PLASMODIUM SPP. 
NEGATIVE SAMPLES 
10.3.1. P. falciparum detection rate
Compared to the P. falciparum cultured parasite panel, 
P. falciparum detection rates of wild type samples were 
generally higher, reflecting the increased antigen content 
of wild type samples. As in Phase 1, the majority of tests 
(35; 85%) detected ≥ 95% of P. falciparum samples at high 
parasite densities but only 6 tests (15%) had this high level 
of detection at low parasite density (200 parasites/μl). All 
of these 6 products targeted HRP2; however 3 products 
targeting pLDH detected > 60% of P. falciparum samples. 
(Figure 8).
Table 4a illustrates detection rates at low and high 
parasite densities based on a delayed second reading if it 
was specifically indicated in the package insert following 
initial negative results at the specified reading time. At the 
low parasite density (200 parasites/μl), the P. falciparum 
detection rate increased for 5 of the 7 products, based on 
the delayed reading.
Figure 8: Phase 2 P. falciparum detection rate of malaria RDTs at low (200) and high (2000 or 5000) 















































































































































































































































































































































































































































































































































































































































































































































































†-  Phase 2 Evaluation Panel included 79 blood samples containing wild type P. falciparum. RDTs - 2 tests x 2 lots at 200 parasites/μl and  
1 test x 2 lots at 2000 parasites/μl
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10.3.2. P. vivax detection rate 
P. vivax was generally less well detected than P. falciparum 
in clinical samples. As Figure 9 illustrates, even at high 
parasite densities (2000 or 5000 parasites/μl) several 
products failed to consistently detect clinical samples 
infected with P. vivax samples and detection rates dropped 
at low parasite density, with only 5 products (25%) detecting 
> 90% of samples. Products targeting pLDH performed 
better than those targeting aldolase. One product had a 
higher detection rate at 200 parasites/μl compared to 2000 
parasites/μl because false positive P. falciparum specific 
test lines at 2000 parasites/μl were counted as incorrect 
or negative results. 
10.3.3.  Combined detection of P. falciparum and 
P. vivax 
Considering combination tests, 3 products had detection 
rates > 60% for both P. falciparum and P. vivax at the low 
parasite density (200 parasites/μl) (Tables 4. 4a). However, 
several performed well at high parasite densities. Two 
pan-specific tests showed high detection rates of both P. 






















































































































































































































































































































































































































































200 (pLDH + aldolase)











†- Phase 2 Evaluation Panel included 20 blood samples containing wild type P. vivax. RDTs - 2 tests x 2 lots at 200 parasites/μl and 1 test x 2 lots at 2000 parasites/μl
Figure 9: Phase 2 P. vivax detection rate of malaria RDTs at low (200) and high (2000 or 5000) parasite 
densities (parasites/μl) according to target antigen type (aldolase, pLDH, aldolase + pLDH)†
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10.3.4. P. falciparum and P. vivax positivity rate 
In addition to detection rate, positivity rate was also 
measured. This puts aside test and lot differences captured 
in detection rate and simply measures the total number 
of times a test returned a positive result. As expected, 
positivity rate was higher but mirrored detection rate of wild 
type P. falciparum and P. vivax samples (Figs 10, 11) with 
one exception. In this exceptional case, the product had a 
very high invalid rate against P. falciparum samples (Table 
4) and invalid test results were included in the calculation 
of positivity rate but excluded from detection rate. 
†- Phase 2 Evaluation Panel included 79 blood samples containing wild type P. falciparum. RDTs - 2 tests x 2 lots at 200 parasites/μl and 



























































































































































































































































































































































































































































































































































































































































































































































Figure 10: Phase 2† wild type P. falciparum detection rate and positivity rate at 200 parasites/μl


























































































































































































































































































































































































































































†- Phase 2 Evaluation Panel included 20 blood samples containing wild type P. vivax . RDTs - 2 tests x 2 lots at 200 parasites/μl and 1 test x 2 lots at 2000 parasites/μl
Figure 11: Phase 2† wild type P. vivax detection rate and positivity rate at 200 parasites/μl
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10.3.5. Band intensity 
Although RDTs are not quantitative, technicians did grade 
positive results according to a standard chart and mean 
band intensity (for positive results) was calculated (Annex 
4 - Tables A4.4, A4.5). There was a positive correlation 
between detection rate and band intensity and reader 
agreement; suggesting that, as expected, strong test bands 
are interpreted more reliably. 
10.3.6. False positive rates
Overall false positive rates were modest, rarely > 10% 
on parasite-free blood bank specimens or Plasmodium 
spp. negative samples containing potentially cross-
reacting factors (Figs 12-15). False positive results were 
seen on both P. falciparum and pan/P. vivax test lines. No 
consistently higher rate of false positive was seen with 
blood abnormalities compared to infectious pathogens; 
however, sample sizes were small. For detailed information 
regarding the blood abnormality or pathogen that generated 
false positive results for a specific product refer to Annex 4 
(Tables A4.10-A4.12). 












































































































































































































































































































































































































































































































































































































































































































































































†- Phase 2 Evaluation Panel included 90 Plasmodium spp. negative samples of which 42 were "clean" negatives. RDTs - 2 tests x 2 lots at 200 parasites/μl and 1 test x 
2 lots at 2000 parasites/μl
*- includes Pf specific lines on combination tests and pan-specific lines on pan-specific only products. 




















































































































































































































































































































































































































































































































































































































































































































































































†- Phase 2 Evaluation Panel included 90 Plasmodium spp. negative samples - 42 clean negatives; 27 samples with blood immunological abnormalities and 21 with non 
Plasmodium spp. infectious pathogens. RDTs - 2 tests x 2 lots at 200 parasites/μl and 1 test x 2 lots at 2000 parasites/μl
*- includes Pf specific lines on combination tests and pan-specific lines on pan-specific only products. 
Figure 13: P. falciparum (P. falciparum test line*) false positive rate against Plasmodium spp. negative 
samples containing potentially cross-reacting blood immunological abnormalities or infectious 
pathogens†





























































































































































































































































































































































































































































†- Phase 2 Evaluation Panel included 90 Plasmodium spp. negative samples - 42 clean negatives; 27 samples with blood immunological abnormalities and 21 with non 
Plasmodium spp. infectious pathogens. RDTs - 2 tests x 2 lots at 200 parasites/μl and 1 test x 2 lots at 2000 parasites/μl
*- includes pan of pv line on combination tests and pan-specific line on pan-specific only products. 
Figure 14: Plasmodium spp. (pan or P. vivax test line*) false positive rate against clean negatives†















































































































































































































































































































































































































































Non malaria infectious pathogens (pLDH)
Immunological abnormalities (pLDH)
Non malaria infectious pathogens (pLDH + aldolase)
Immunological abnormalities (pLDH + aldolase)











†- Phase 2 Evaluation Panel included 90 Plasmodium spp. negative samples - 42 clean negatives; 27 samples with blood immunological abnormalities and 21 with non 
Plasmodium spp. infectious pathogens. RDTs - 2 tests x 2 lots at 200 parasites/μl and 1 test x 2 lots at 2000 parasites/μl
*- includes pan of pv line on combination tests and pan-specific line on pan-specific only products. 
Figure 15: Plasmodium spp. (pan or P. vivax test line*) false positive rate against Plasmodium spp. 
negative samples containing potentially cross-reacting blood immunological abnormalities or infectious 
pathogens†
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Figure 16 and 17 illustrates that high rates of detection of P. falciparum or of P. vivax were not associated with a significant 
overall increase in false positive rates.





















Figure 16: P. falciparum false positive rate19 versus P. falciparum detection rate at low (200) parasite 
density (parasites/μl)





















Figure 17: P. vivax false positive rate versus P. vivax detection rate at low (200) parasite density 
(parasites/μl)
10.3.7. Inter-reader variability 
Each RDT result was read twice, the first, according to the 
manufacturers minimum reading time and a second reading 
was performed by a different technician within one hour. 
The mean time between readings for each product can 
be found in Tables A4.2, A4.3 (Annex 4). Figures 18 and 
19 illustrate that for many products, the second reading 
yielded more positive results. However, for two products 
Reader 2 results returned fewer positive results secondary 
to the fading of weak test band signals. In the case of 7 
products20 manufacturers specifically indicated that a 
second reading should be performed if the initial results 
were negative. Results are therefore reported on the basis 
of the delayed reading in Tables 3a, 4a and in Annex 4 
(Tables A4.1a, A4.4a-A4.12a)
20 Parascreen Rapid Test for Malaria (Pan/Pf) Device, Parabank Rapid Test 
for Malaria Pan (Device), Malascan Rapid Test for Malaria Pf/Pan (Device), 
ImmunoQuick Malaria + 4, Malaria Pf/vivax, Wondfo One Step Malaria Pf/
Pan Whole Blood Test, FirstSign – ParaView-2 (Pv + Pf) Card Test.
19
19  On the clean negative panel, only.

















































































































































































































































































































































































































































































































































































































































































































































































Figure 18: Wild type P. falciparum detection rate according to first and second readings at 200 parasites/μl
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11. HEAT STABILITY 
A single P. falciparum culture sample was used as the 
reference sample for heat stability testing. Variations in 
baseline performance reflect inter-test variation as the 
sample at 200 parasites/μl was at the limit of detection of 
some products. 
Several products were stable, meaning that they detected 
a P. falciparum cultured sample the same number of times 
at baseline and following incubation for 2 months (75% 
humidity) at 4°C, 35°C and 45°C. Detailed results are 
presented in Tables A4.13-A4.15 (Annex 4); in Table 5 and 
Figs 20-29, the results of both lots are combined (maximum 
score 20; 10 tests per lot). 
Overall products (including HRP2 and pan test lines) were 
significantly more stable against samples with high (2000 
or 5000) compared to low parasite densities, Figures 21, 
23, 25 and Figures 20, 22, 24, respectively. For several, 
P. falciparum and combination tests, HRP2 test lines showed 
a high degree of stability at 35°C but several dropped off 
at 45°C. Some products showed an improved performance 
with incubation (Figs 22, 26). Baseline detection based on 
pan test lines was lower than baseline HRP2 test line results 
and the pan test lines of many products had poorer stability 
than HRP2 test lines. 
Ultimately, there are products in each test category (Pf only, 
combination, pan only) that show good consistent baseline 
detection and heat stability up to 45°C for 2 months. 
The summary results of heat/thermal stability testing are 
presented in Table 5.
11.1. P. FALCIPARUM TEST LINES 
Figure 20: Heat stability of P. falciparum specific (HRP2) test line of P. falciparum only tests against 







Parahit-f TEST DEVICE FOR FALCIPARUM MALARIA
Paracheck Pf Rapid Test for P. falciparum Malaria (Dipstick)
Paracheck Pf Rapid Test for P. falciparum Malaria (Device)
Malaria Rapid Pf
ICT Malaria Pf Rapid Test (ML01)
Hexagon Malaria
FirstSign – Malaria Pf Card Test
CareStart Malaria HRP2 (Pf)
First Response Malaria Ag HRP2
Immunoquick Malaria Falciparum
Malaria Plasmodium falciparum Rapid test Device (Whole blood)
Parahit-f DIPSTICK FOR FALCIPARUM MALARIA
SD BIOLINE Malaria Ag Pf 
Advantage P.f. Malaria Card
ADVANCED QUALITY TM One Step Malaria (p.f.) Test (whole blood)
ADVANCED QUALITY TM  MALARIA (p.f) POCT  45°C35°CBaseline
No. of positive 
results from 
two lots
Figure 21: Heat stability of P. falciparum (HRP2) test specific line of P. falciparum tests against a 




Parahit-f TEST DEVICE FOR FALCIPARUM MALARIA
Paracheck Pf Rapid Test for P. falciparum Malaria (Device)
Hexagon Malaria
FirstSign – Malaria Pf Card Test
ADVANCED QUALITY TM One Step Malaria (p.f.) Test (whole blood)
ADVANCED QUALITY TM  MALARIA (p.f) POCT
Advantage P.f. Malaria Card, CareStart Malaria HRP2 (Pf)
First Response Malaria Ag HRP2
ICT Malaria Pf Rapid Test (ML01)
Immunoquick Malaria Falciparum
Malaria Plasmodium falciparum Rapid test Device (Whole blood)
Malaria Rapid Pf
Paracheck Pf Rapid Test for P. falciparum Malaria (Dipstick)
Parahit-f DIPSTICK FOR FALCIPARUM MALARIA
SD BIOLINE Malaria Ag Pf
45°C35°CBaseline
No. of positive 
results from 
two lots
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Figure 22: Heat stability of P. falciparum specific (HRP2) test line in combination tests against a low density 






Wondfo One Step Malaria Pf/Pan Whole Blood Test
CareStart Malaria HRP2/pLDH (Pf/PAN) COMBO
SD BIOLINE Malaria Ag Pf/Pan
Binax Now  Malaria
First Response Malaria Ag Combo (PLDH/HRP2)




SD BIOLINE Malaria Ag
Quickstick Malaria Antigen Test
Parascreen Rapid Test  for Malaria Pan/Pf (Device)
ParahitTotal Device Rapid Test for P. falciparum and Pan Malarial Species
OptiMAL- IT
OnSight – ParaQuick (Pan, Pf)
One Step Malaria Antigen Strip
Malascan Rapid Test for Malaria Pf/Pan (Device)
Malaria P.F/VIVAX
Hexagon Malaria Combi
FirstSign – ParaView-2 (Pv + Pf) Card Test
Advantage Mal Card
 AZOG Malaria pf (HRP-II)/pv (pLDH) Antigen Detection Test Device
45°C35°CBaseline
No. of positive 
results from 
two lots
Figure 23: Heat stability of P. falciparum (HRP2) test specific line in combination tests against a 







Quickstick Malaria Antigen Test
One Step Malaria Antigen Strip
Parascreen Rapid Test  for Malaria Pan/Pf (Device)
SD BIOLINE Malaria Ag Pf/Pan
Binax Now  Malaria
ParahitTotal Device Rapid Test for P. falciparum and Pan Malarial Species




FirstSign – ParaView-2 (Pv + Pf) Card Test
Advantage Mal Card
CareStart Malaria HRP2/pLDH (Pf/PAN) COMBO
First Response Malaria Ag Combo (PLDH/HRP2)
ICT Malaria Combo Cassette Test (ML02)
Immunoquick Malaria +4, Malaria Rapid Combo
Malascan Rapid Test for Malaria Pf/Pan (Device)
OnSight – ParaQuick (Pan, Pf)
SD BIOLINE Malaria Ag
AZOG Malaria pf (HRP-II)/pv (pLDH) Antigen Detection Test Device
45°C35°CBaseline
No. of positive 
results from 
two lots
Figure 24: Heat stability of pan-line of pan-specific tests against a low density P. falciparum sample (200 






Parabank Rapid Test for Malaria Pan (Device)
CareStart Malaria pLDH (PAN)
Advantage Pan Malaria Card
45°C35°CBaseline
No. of positive 
results from 
two lots
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Figure 25: Heat stability of pan-line of pan-specific tests against a high density P. falciparum sample 




Parabank Rapid Test for Malaria Pan (Device)
CareStart Malaria pLDH (PAN)
Advantage Pan Malaria Card
45°C35°CBaseline
No. of positive 
results from two 
lots
11.2. PAN TEST LINES
Figure 26: Heat stability of pan-line of combination tests against a low density P. falciparum sample 






Wondfo One Step Malaria Pf/Pan Whole Blood Test
SD BIOLINE Malaria Ag Pf/Pan
SD BIOLINE Malaria Ag
OptiMAL- IT
One Step Malaria Antigen Strip
Quickstick Malaria Antigen Test
Malascan Rapid Test for Malaria Pf/Pan (Device)
Malaria Rapid Dual
Malaria Rapid Combo
ICT Malaria Combo Cassette Test (ML02)
First Response Malaria Ag Combo (PLDH/HRP2)
CareStart Malaria HRP2/pLDH (Pf/PAN) COMBO
Binax Now  Malaria
Parascreen Rapid Test  for Malaria Pan/Pf (Device)
ParahitTotal Device Rapid Test for P. falciparum and Pan Malarial Species
Advantage Mal Card




OnSight – ParaQuick (Pan, Pf)
45°C35°CBaseline
No. of positive 
results from 
two lots
Figure 27: Heat stability of pan-line of combination tests against a high density P. falciparum sample 





20 Wondfo One Step Malaria Pf/Pan Whole Blood Test
SD BIOLINE Malaria Ag Pf/Pan
SD BIOLINE Malaria Ag
Quickstick Malaria Antigen Test
One Step Malaria Antigen Strip
Parascreen Rapid Test  for Malaria Pan/Pf (Device)




OnSight – ParaQuick (Pan, Pf)




ICT Malaria Combo Cassette Test (ML02)
Binax Now  Malaria
 AZOG Malaria pf (HRP-II)/pv (pLDH) Antigen Detection Test Device
Advantage Mal Card
CareStart Malaria HRP2/pLDH (Pf/PAN) COMBO
First Response Malaria Ag Combo (PLDH/HRP2)
45°C35°CBaseline
No. of positive 
results from 
two lots
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Figure 28: Heat stability of pan-line of pan-specific tests only against a low density P. falciparum sample 






Parabank Rapid Test for Malaria Pan (Device)
CareStart Malaria pLDH (PAN)
Advantage Pan Malaria Card
45°C35°CBaseline
No. of positive 
results from 
two lots
Figure 29: Heat stability of pan-line of pan-specific tests only against a high density P. falciparum 




Parabank Rapid Test for Malaria Pan (Device)
Advantage Pan Malaria Card
CareStart Malaria pLDH (PAN)
45°C35°CBaseline
No. of positive 
results from 
two lots
12. EASE OF USE 
DESCRIPTION 
After becoming proficient at using a product, two technicians 
jointly produced an agreed assessment of product usability. 
The results are presented in Table 6. 
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13.  DISCUSSION OF KEY 
FINDINGS
This report describes the performance of many of the 
available malaria antigen-detecting RDTs manufactured 
under the ISO-13485 quality standard. Malaria RDTs have the 
potential to provide a huge step forward in the management 
of febrile illness in malaria-endemic areas. To be useful in 
this context, malaria RDTs must have adequate:
1. sensitivity, to detect nearly all clinically-significant 
cases of malaria;
2. specificity, to accurately discriminate non-malarial 
febrile illness from malaria, to ensure appropriate 
management and accurate disease monitoring;
3. stability, for accuracy to be maintained after transport 
and storage in ambient conditions; 
4. ease of use and safety, to allow safe and correct 
preparation, and correct interpretation of results.
In order to assist national malaria control programmes, and 
other procurement agencies to select products appropriate 
to their needs, malaria RDTs were evaluated in terms of 
these four major requirements. The blood panel used 
successfully discriminated between the RDTs evaluated, 
showing a considerable range of performance. Importantly, 
a number of products demonstrated a high rate of antigen 
detection combined with a low false-positive rate and good 
heat (thermal) stability, attributes essential if they are to be 
relied on as a basis for malaria treatment decisions in most 
endemic populations.
The principal results in this report are presented in Tables 
3, 3a, 4, 4a. The table groups the RDTs by type, depending 
on what they aim to detect, e.g. P. falciparum only, P. 
falciparum and non-falciparum species, or all malaria 
species without discrimination. Detection rates at both high 
and low concentrations are presented, as are false-positive 
rates, and the percentage of invalid test results. Tests in 
each category are listed alphabetically, but the results are 
colour-coded to assist the reader in quick interpretation of 
the data. These colour codes are intended to be used to 
quickly compare performance in the different categories 
and not as performance cut-offs to guide test selection or 
procurement. When choosing an appropriate product, it is 
important to also review the stability results (Table 5) in 
the context of the expected conditions of transport and 
storage of the RDTs in the field.
This evaluation is performed against a standardized panel 
of frozen blood samples by experienced technicians in a 
research laboratory and is not a field evaluation of RDT 
accuracy in a specific epidemiological context in the hands 
of intended users. The panel is designed to mimic fresh 
blood samples from real cases as closely as possible, while 
allowing direct comparison of a large number of products 
simultaneously in a manner that controls for confounding 
factors and is calibrated to a level likely to discriminate 
performance differences of various products. In interpreting 
the results, it is therefore important that the following 
notes are taken into account.
13.1.  PARASITE DETECTION AND ITS 
RELATIONSHIP TO SENSITIVITY 
Evaluation of the RDTs against the parasite-positive panel 
with parasite densities of 200 parasites/μL (Figs 8, 9) 
revealed a wide range of detection rates between products. 
Testing at higher parasite densities (2000 or 5000 parasites/
μL) was less able to demonstrate small differences in 
performance. As two tests each from two different lots 
were tested, and as all four results had to be positive for 
a sample to be considered detected by an RDT, a positive 
result indicated both the ability of a product to detect the 
target antigen in the sample, and to do this consistently 
(both tests from both lots). 
The rate of detection against the panel used in this 
evaluation is expected to differ from the sensitivity for 
detection of malaria in a specific clinical setting. There are 
five main reasons for this:
i. Performance may vary between lots or batches of the 
same product. Variability in lot performance is an issue 
with all diagnostics, and it can not be guaranteed that 
the results found here will predict results from different 
RDT lots that are purchased. It is important to test lots 
prior to distribution to the field, to ensure that expected 
performance is maintained (Section 14.2). 
ii. In clinical settings, patients show a wide variety of 
parasite densities, the range of which will depend on 
the local epidemiology of the disease. The magnitude of 
the parasite density in the population tested affects the 
clinical sensitivity of the test. Detection rates in the test 
panel of blood samples diluted to 200 parasites/μL are 
likely to underestimate the clinical sensitivity of an RDT 
in many situations, especially in high-transmission areas 
where symptomatic patients often have much higher 
parasite densities in their blood. Many tests that showed 
only moderate sensitivity against the 200 parasite/μL 
panel may perform very well in such settings, as shown 
by the high performance of most products against the 
panel set at 2000 parasites/μL.
 Importantly, when interpreting Figs E1, 7, 8 and 9 
and the colour coding in Tables 3, 3a, 4, 4a the small 
differences in detection rates found among the better-
performing RDTs in this evaluation are unlikely to result 
in noticeable differences in clinical sensitivity, and 
other issues such as stability, cost, or ease of use and 
manufacturing capacity may be more important factors 
in test selection. 
 When considering the parasite density of the target 
populations and the likely field sensitivity of RDTs, 
it is important to note that, even in areas with high 
transmission and strong malaria immunity, populations 
may include individuals with low parasite densities but 
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clinically significant infections (e.g. young children, 
pregnant women, others with low immunity). The 
ability to detect low parasite density infections reliably 
therefore remains important in these cases. 
iii. Performance of tests against the challenge panel may 
not directly relate to sensitivity in clinical testing as 
there is variability in the amino acid sequence of the 
HRP2 antigen of P. falciparum that may affect the 
ability of RDTs to detect it. In certain P. falciparum 
parasites the HRP2 antigen may not be detectable at 
all. Specifically, there is evidence that P. falciparum 
strains in some areas of South America may express 
HRP2 antigens very poorly or not at all.21 If a significant 
proportion of parasites in a given area do not express 
HRP2, it is necessary to use tests detecting other target 
antigens (pLDH or aldolase). The distribution of such 
strains is currently being mapped.
iv. The methods used to transport and store tests can 
affect their field sensitivity. All the tests used in this 
evaluation were shipped and stored under conditions 
intended to safeguard against degradation caused by 
high temperature or other extreme conditions. If similar 
precautions are not taken with purchased RDTs, loss 
of performance could result. Ambient temperatures of 
storage conditions vary widely in settings where these 
tests are commonly used, as do temperatures during 
transport, and requirements for heat stability of a 
product will therefore differ.
v. Diagnostic sensitivity and specificity are dependent 
on the quality of preparation and interpretation of 
the tests. Highly trained individuals performed all the 
testing in this product evaluation. In clinical settings, 
malaria RDTs will often be used by health workers with 
limited training and supervision. Simplicity of design 
and clearly-interpretable results will have an influence 
on ensuring that the technical proficiency of a product 
translates into accurate diagnosis in the field.
13.2.  FALSE POSITIVE RATE AND SPECIFICITY 
False positive rates are reported here against a panel 
of 'clean' negative samples taken from blood donated 
in low-transmission settings by people without malaria 
symptoms. Also calculated were false positive rates against 
a smaller number of samples with specific characteristics 
that affect the likelihood of a false-positive result from 
an immuno-diagnostic test (e.g. rheumatoid factor, anti-
nuclear antibody), or that may be of significance in a specific 
population (e.g. leishmaniasis, dengue). The importance of 
these results will vary with the intended area of use. High 
false positive rates against samples of blood from dengue 
patients, for example, may not be a significant factor to 
consider in regions where dengue does not occur. In view 
of the small number of samples in each category in this 
evaluation, the results should be considered primarily as a 
guide, to highlight potential cross-reactions that will require 
21 WHO 2009, unpublished data. Clarification of these findings will be 
made in following publications of the WHO-FIND malaria RDT evaluation 
programme.
close monitoring if relevant to the target population. 
In general, it is preferable to procure a product with a 
low rate of false-positive reactions. In the case of many 
diagnostic tests, a trade-off must be made between a 
preference for a high rate of antigen detection (sensitivity) 
and a low false positive rate (specificity). The context 
in which the test will be used will guide the relative 
importance of these two factors in choosing one product 
over another. In this evaluation there was no correlation 
of loss of sensitivity associated with high specificity, with 
a number of products attaining both a high detection rate 
(predicting a high sensitivity) and a low false-positive rate 
(predicting a high specificity).
13.3. HEAT (THERMAL) STABILITY 
RDTs in this evaluation were held for two months at 35°C 
and 45°C and then retested to evaluate stability at these 
temperatures. The importance of thermal stability will vary 
according to the ambient conditions under which a product 
is expected to be transported and stored. Thus, stability at 
high temperatures will be vital if an RDT is to be stored at 
clinic level in a country where ambient temperatures can 
reach 45°C in the hot season, but less critical in a high-
altitude or cooler tropical environment where temperatures 
rarely rise above 35°C. Most of the commercial RDTs 
list 30°C as the maximal storage temperature. Higher 
temperatures were used for this evaluation because it is 
unusual for malaria–endemic countries to have maximum 
ambient temperatures less than 35°C, though the use of 
cool storage methods will also allow the use of less heat-
stable products. Where transport and storage of RDTs is 
likely to occur at high ambient temperatures, heat (thermal) 
stability should be seen as a significant factor in ensuring 
maintenance of sensitivity. 
High humidity will accelerate the degradation of malaria 
RDTs and other lateral flow tests. All the products in this 
evaluation were packaged in individual envelopes that 
contain a desiccant and are designed to be moisture-proof. 
This allows the user to open the envelope of a specific test 
at the time of use, limiting exposure to high humidity. 
During the stability testing phase of this evaluation, RDTs 
were stored at 75% humidity. The packaging should, if in 
good condition, protect the contents from exposure to 
high humidity during storage. As such, the stability testing 
results presented here provide an assessment of both the 
stability of the RDT and the quality of its packaging.
Several products showed high stability at the temperatures 
and time periods used in this evaluation. In general, pan-
specific lines (pLDH and aldolase) were less stable than HRP2 
test lines, but there was overlap between the antibodies 
against these targets with some pLDH tests maintaining 
high positivity rates after 2 months at 45°C. A small number 
of products showed a consistent improvement in positivity 
rate after incubation, for reasons which are not clear.
Though temperature and humidity were held constant in 
this evaluation, in the field temperatures fluctuate with 
time of day and season. While two months’ storage at a set 
temperature can not accurately predict long-term stability 
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under field conditions, loss of parasite detection over this 
period indicates a likelihood that significant sensitivity will 
be lost when similar or higher storage temperatures comprise 
a significant amount of the storage time, and indicates 
likelihood of a higher susceptibility to degradation during 
short periods of exposure to much higher temperatures, 
such as during transport (12, 13).
13.4. EASE OF USE DESCRIPTION
The sensitivity and specificity of RDT results will depend to 
some extent on the quality of preparation and interpretation 
of the test. In general, a simpler format with fewer steps 
or fewer extraneous materials is likely to be prepared and 
interpreted more reliably. Thus, cassette-format RDTs are 
generally more reliably prepared and interpreted than 
products in dip-stick format (14). The extra cost involved in 
such a format may be offset by the advantages of increased 
accuracy and, in some cases, less additional equipment 
required to perform them.
The method of blood transfer from the patient to the test 
is important for the safety of the user, and for the accuracy 
of volume of blood transferred. Devices for blood transfer 
are supplied with RDTs, and vary widely in design. The 
performance of blood transfer devices was not formally 
assessed in this evaluation, as blood was transferred from 
a tube by a micro-pipette to ensure the manufacturer-
specified volume was used. Programmes procuring RDTs 
should consider the adequacy of the blood transfer device 
supplied, including previous experience of health workers 
and the costs and time required for re-training. It may often 
be appropriate to discuss with manufacturers changing the 
blood transfer device from that normally supplied. 
Clarity of results is important to test interpretation. A clearly 
visible (intense) test line is less likely to be overlooked than 
a line that is barely visible. While reading proficiency and 
adequate work places should always be ensured, health 
workers may sometimes have sub-optimal vision or work in 
conditions of inadequate lighting. The intensity of the line 
of the test band is closely associated with error rate and 
with the detection rate found in this report (Tables A4.4, 
A4.4a, A4.5, A4.5a). 
The importance of format and simplicity of test design 
will depend on the intended end-users. Trained laboratory 
technicians may handle a complicated procedure more 
reliably than village-level volunteers with limited 
supervision. In all cases, specific proficiency-based training 
and adequate supervision should be included in any RDT-
based diagnostic programme, and clear instructions should 
be provided in a language and format appropriate for the 
end-user22(14-16). 
13.5. INTER-LOT VARIABILITY 
This testing programme evaluated only two production 
lots of each product. Malaria RDTs are complex biological 
22 See www.wpro.who.int/sites/rdt for generic examples
products made of components commonly supplied from 
multiple sources, and subject to various conditions during 
manufacture that may affect the quality of the final 
product. All manufacturers entered in this evaluation have 
current ISO 13485:2003 certification, a standard designed 
to give assurance of consistency of quality of final product if 
correctly implemented. The results presented here indicate 
that inter-lot variability does occur, and WHO strongly 
recommends that a sample of RDTs from each production 
lot be tested prior to dissemination to the field to ensure it 
meets an appropriate standard. This can be facilitated by 
WHO (see section 14.2). 
Since inter-test variability also occurs, this will be detected to 
some extent by routine lot testing. Ensuring manufacturers 
have good manufacturing standards should minimize the 
likelihood of inconsistencies due to poor practice in the 
manufacturing process.
13.6. INTER-READER VARIABILITY
All RDTs in this evaluation were interpreted by two 
technicians, blinded to the other technicians' results. The 
first reading was performed at the minimum time specified 
by the manufacturer to obtain a result, and this reading 
is used as the primary determinant of RDT performance. 
The second reading was obtained later, usually within 45 
minutes, always within 90 minutes. Where a manufacturer 
specifically instructed in the product insert that 
interpretation be deferred if a result was not visible at the 
time of the initial reading, the result of the second reader 
was also reported. 
The difference between the two readings reported here 
was therefore subject to the stability of the result: if a 
test became positive after the minimum time specified 
by a manufacturer to obtain a result, this appeared as a 
discrepancy between the two readers. The intensity of the 
test lines of antigen-detecting RDTs was also dependent 
on the amount of available antigen. Therefore, at the low 
parasite-densities used in this evaluation where a test line 
intensity was close to the limit of human visual perception 
(i.e. close to the operational limits of the product), inter-
reader discrepancies were more likely to occur. 
Early, accurate and stable RDT results are important in the 
context of busy clinical work. Specifying a single reading 
time at which the result can be determined to be negative 
or positive is also an advantage in terms of training and 
consistency of use. It is recommended that low inter-reader 
variability and early availability of result be considered in 
making decisions on procurement, but that the stability of 
the result (an adequate time period during which the result 
may be read) is also ensured.
13.7. TARGET ANTIGENS AND SPECIES
Malaria RDTs included in this evaluation detect one or more 
of three parasite antigens (HRP2, pLDH, and aldolase) in 
various combinations. HRP2 is present only in P. falciparum, 
whereas aldolase and pLDH are present in all four species 
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and may be used as pan or all-species targets. Some tests 
use differences in pLDH sequences between species as a 
means to differentiate P. falciparum from P. vivax and other 
species. There is considerable overlap in the detection 
rates of products targeting the different antigens in this 
evaluation. While the products with the highest detection 
rates for P. falciparum targeted HRP2, a number of pLDH-
detecting products demonstrated high detection rates 
against P. falciparum and P. vivax. The stability of tests 
targeting these different antigens also overlapped.
The choice of RDT should take target antigen into account: 
HRP2-detecting RDTs should not be used in areas where 
high rates of HRP2 non-expression occur. Tests detecting 
only HRP2 (without pLDH or aldolase lines) will have limited 
utility where non-falciparum malaria is common. pLDH (and 
possibly aldolase) RDTs may have further advantages where 
antigen persistence (common with HRP2) may result in a 
high false-positive rate in areas where early re-testing in 
the weeks soon after treatment is common. 
The required sensitivity of a test may also vary with species; 
a less sensitive test may be acceptable for detection of P. 
vivax compared to detection of P. falciparum, as severe 
outcomes due to missed diagnoses are less likely. Use of a 
sufficiently sensitive pan-specific test may be appropriate 
in areas where both P. falciparum and P. vivax occur, if all 
infections were to be managed initially as a P. falciparum 
infection with artemisinin-based combination therapy 
(ACT). 
It should be noted that pan-species tests were not evaluated 
for detection of P. ovale or P. malariae due to lack of sources 
of suitable mono-species infections of these parasites.
14.  ADDITIONAL 
MEASURES TO 
ENSURE QUALITY 
AND UTILITY OF RDT 
TESTING
This report provides data to guide programmes in selecting 
products likely to perform to a high standard in the 
particular contexts in which the programme operates. The 
final decision on product selection requires that this data 
be considered in a systematic way, often with other data 
obtained from the manufacturer and other sources. An 
algorithm to guide this process, adapted from the quality 
assurance guide of the WHO Global Malaria Programme 
(found at www.wpro.who.int/sites/rdt) is given in Annex 5.
While malaria RDTs have application in a number of settings, 
the area in which they have the greatest impact on public 
health is in extension of access to accurate, parasite-based 
diagnosis of malaria to regions and populations where 
good quality microscopy-based analysis is impractical to 
maintain. This currently applies to most people at risk of 
malaria in endemic countries (1). In many settings where 
RDTs have been introduced, the true rate of parasitaemia 
has been found to be dramatically lower than expected, 
allowing health systems to save on wasted RDTs and to focus 
appropriately on the management of non-malarial causes 
of fever, including pneumonia and sepsis. A successful RDT 
programme must therefore address not just malaria but also 
the management of other common and severe febrile illness 
that occur locally as differential diagnoses of malaria, if the 
potential full public health impact of an RDT programme is 
to be achieved. 
14.1. BEYOND PROCUREMENT
RDTs are often added to a procurement list that includes 
mainly chemical agents such as pharmaceuticals, bednets, 
and insecticides. Unlike these products, however, diagnostic 
tests are relatively more complex to implement, not least 
because they represent the starting point, not the end point, 
in a health system intervention, and their use presumes 
that appropriate patient management, based on testing, 
will follow. Thus, successful introduction of RDTs requires 
careful planning going beyond rational procurement 
to ensure consistent supplies of all necessary materials 
(including gloves, sharps disposal containers, and supplies 
required for further case management), training of users, 
and community sensitization. This extends beyond malaria 
management to management of other febrile diseases and 
health service delivery systems. 
This report provides information to guide procurement 
of RDTs within this framework. A number of factors 
beyond performance characteristics reported here 
must influence procurement decisions. An example 
algorithm to guide these decisions is given in Annex 5. 
Details of implementation will vary widely between 
programmes according to local capacity and needs. 
Further recommendations on budgeting, planning and 
implementation can be found in Annex 6.
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14.2. LOT TESTING 
Complementary to the product testing programme, 
WHO and FIND currently support three laboratories that 
perform continual quality assurance of RDTs in the form 
of lot testing. These lot testing facilities respond to formal 
requests from national malaria programmes, manufacturers, 
and procurement bodies and assess the quality of RDT lots 
when they arrive in country, before distribution. Testing is 
performed with carefully prepared blood panels such as 
those used for this evaluation. A number of other national 
institutions have also developed this capacity. Lot-testing 
reassures countries that the product they have purchased 
is performing to a high standard and helps to ensure that 
manufacturers produce consistently good lots and improve 
their products. 
Countries and/or manufacturers ship between 125-175 RDTs 
to the regional lot testing centre where they are evaluated 
against a small panel of parasites at high and low parasite 
densities and negative samples. They are subsequently 
incubated at a temperature close to the manufacturer's 
specified storage temperature and retested every three 
months until their expiry date. Initial results are available 
after five days and then sent at regular intervals. Details of 
the protocol can be found in a published methods manual 
for lot testing.23
All countries and procuring agencies are encouraged to 
participate in the lot testing programme and in the near 
future it is intended to publish overall performance of 
products submitted for lot testing. 
23 WHO, Rapid Diagnostic Tests for Malaria: Methods Manual for Laboratory 
Quality Control Testing. Version 5a. 2008, WHO - Regional Office for the 
Western Pacific. Available at: www.wpro.who.int/sites/rdt/documents/
list.htm
15. CONCLUSIONS 
This study is a landmark in the field of malaria RDT 
evaluations because of the number of products evaluated 
and its comprehensiveness including, samples with low and 
high parasite densities, detailed parasite characterization 
(antigen quantification, HRP 2,3 characterization) multiple 
test lots and heat stability assessment. New laboratory 
methods were developed and validated to support parasite 
characterization and this work generated new findings 
regarding the variation in antigen content at similar 
parasite densities and the variation in the structure and 
expression of HRP proteins. The latter will critically inform 
RDT selection in several endemic countries.
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ANNEX 5: EXAMPLE ALGORITHM FOR SELECTING A MALARIA RDT
 
 
Select (from Table 4, 4a) an RDT with sufficiently high detection rate,
















































5. Other considerations:  
Box size: How many fever cases expected in 3 months
(if less than one box, request reduced box size) 
 
Next Step: Finalize short-list of suitable RDTs  
Sometimes preferences will be incompatible, in which case, prioritize 
the importance of the categories above for your programme.
Distinguish non-Pf from  




Combination test  
HRP2 - pLDH  
HRP2 - aldolase  
pLDH - pLDH  
Pf-only test 
HRP2  
pLDH (may be combined with 
pan-specific pLDH)  





High stability demonstrated, 
and specified temperature 
e.g. 35°C  
Storage temperature less 
critical  
Accept lower stability and 
<35°C specified storage   
For use by health workers 




Cassette design , few 
steps, lancet, swabs etc. 
included in package  
Design less critical  
Include dipsticks  
Test-only packaging   
Likely to use for re-testing soon after




pLDH-detecting for  
P. falciparum 
Antigen persistence 
not critical  
HRP2 or pLDH for 
P. falciparum  
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1. Contact manufacturers and request:
a. Quoted price (include necessary accessories, delivery to 
country, and staggered delivery in 2-3 batches over 12 
months)
b. Request heat stability data as evidence of 
manufacturer's stated storage temperature and 
shelf-life
c. Request sample of product to assess format, ease of use, 
compatibility of other materials with health system 
requirements
3. Options to improve implementation:
a. Negotiate replacement of product if supplied product 
fails lot-testing after delivery by a method approved by 
manufacturer / WHO-coordinated laboratory
b. Develop appropriately-formatted instructions in appro-
priate language and consider their inclusion of these in 
kits at the manufacturing site
c. Negotiate delivery dates for staggered delivery to reduce 
in-country storage times, ensure long (e.g. 18 months) 
shelf-life after delivery
2. Assess experience of others:
If possible, obtain written assessments of field experience 
from other countries / programmes that have experience in 
using the product
4. Organize lot-testing prior to dispersal to the field
Make preliminary procurement 
decision, then consider…
 
CHOOSING SPECIFIC PRODUCT FROM RDT SHORT-LIST
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ANNEX 6:  INTRODUCING RDT-BASED MALARIA DIAGNOSIS INTO NATIONAL PROGRAMMES
As parasite-based diagnosis is introduced at smaller 
clinics and village level for case management, a large 
number of challenges arise not only in logistical 
administration but also in managing the health-seeking 
and health-providing behaviour of patients and health 
workers. These can be addressed by a systematic 
approach to planning, implementation, monitoring and 
evaluation of the diagnostic programme; a process that 
must commence well before RDTs are procured. The 
following information is derived from existing WHO 
documents addressing this area.22 More information 
may be obtained at www.wpro.who.int/sites/rdt .
Many health workers and communities will have 
been taught that “fever equals malaria unless proven 
otherwise”. Introducing RDTs will demonstrate that 
this is not the case. To have an impact on anti-malarial 
diagnosis and treatment, RDTs must be seen to provide 
an accurate diagnosis by both health workers and 
patients alike, that is, they must be as good or better 
than those relied on previously. A health worker will 
also need a good alternative to anti-malarial medicines 
for the management of parasite-negative febrile 
patients. To achieve and maintain confidence in RDT-
based diagnosis, a good quality assurance system must 
be in place (detailed elsewhere on this website). There 
must be satisfactory education of health workers, 
and widespread community sensitization. Knowledge 
of other causes of fever will be necessary to develop 
appropriate management algorithms for parasite-
negative cases. 
At the national level, regulatory requirements may 
need to be developed to control the importation and 
22 Developed by WHO Regional Office for the Western Pacific and the WHO 
Global Malaria Programme, with support from the Uganda Ministry of 
Health (National Malaria Control Programme), Management Sciences for 
Health (MSH), and other partners.
use of malaria RDTs, and new procedures for storage, 
distribution and inventory management, such as 
those used for medicines, may need to be developed. 
If changing from a different product or mode of 
diagnosis, an adequate phase-out plan for this must 
also be developed.
This requires a clear strategic plan to be developed 
well in advance of RDT introduction, with a clear 
timeline to ensure that the various components of the 
RDT programme are in place at the right time. A focal 
person, or persons, will be needed to coordinate the 
overall implementation plan and ensure that the various 
agencies that may be involved understand the process 
and their particular roles. To achieve this, funding for 
the programme must include a significant component 
for planning and coordination, sensitization/IEC, 
training, quality assurance, monitoring and supervision, 
and logistics, in addition to procurement. Without this, 
much of the funds expended on RDTs may be wasted, 
and a loss of confidence in RDT-based diagnosis 
may hinder the process of strengthening appropriate 
malaria case management.
An example of a national implementation plan is shown 
below. This will need to be modified considerably for 
each programme, preferably through a collaborative 
process involving all the major agencies concerned in 
its implementation. Budgeting for all the components 
of the programme at the outset is vital. An example of 
components to be considered in an overall budget is 
shown in Figure A6.1.
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Summary of introduction plan (see following page)
Program planning and management
 Identify key stakeholders, and secure commitment for introduction of RDTs
 Establish working group and develop terms of reference
 Identify specific focal person(s) responsible for day to day oversight of the implementation plan
 Develop a timeline, scope, and budget for implementation
 Identify human and other resource needs, and a strategy for accessing them
 Review and update, if needed, case-management algorithms for malaria and other causes of febrile illness
Policy and regulatory issues
 Develop appropriate regulatory documents if required
 Register RDT products
Procurement of RDTs
 Develop product specifications and packaging requirements
 Develop product short-list
 Conduct quantification (estimation of needs)
 Procure RDTs
 Procure sharps boxes, gloves etc.
Logistics
 Develop distribution plan
 Train logistics and storage personnel in handling and distribution of RDTs
 Implement a system for data collection and information flows
 Arrange for appropriate transport and storage
 Review and strengthen inventory management, as needed
 Develop a plan for discontinuation and disposal of other diagnostic supplies, if appropriate
Quality Assurance
  Develop mechanisms for assessing samples at a national level (lot-testing), and regular (and random) testing 
at the level of use (e.g. microscopy-sentinel sites)
 Implement post-marketing surveillance
Training and communication
 Develop appropriate training and supervision materials 
 Train health workers in case management and managing commodities
 Train in RDT use
 Develop and implement a program for community education/ sensitization
Monitoring and Evaluation
 Implement effective supervision and monitoring
 Strengthen recording and reporting procedures
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Figure A6.1 Example malaria RDT implementation budget
Below is an example of major components of a programme budget to be considered when introducing RDTs 
into a malaria programme. Without adequate provision for each of these factors, it is likely that an RDT-
based diagnostics programme will fail to achieve its goals. These components should therefore be addressed in 
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